WO2008072621A1 - ガストリン放出ペプチド前駆体の免疫学的測定方法 - Google Patents
ガストリン放出ペプチド前駆体の免疫学的測定方法 Download PDFInfo
- Publication number
- WO2008072621A1 WO2008072621A1 PCT/JP2007/073854 JP2007073854W WO2008072621A1 WO 2008072621 A1 WO2008072621 A1 WO 2008072621A1 JP 2007073854 W JP2007073854 W JP 2007073854W WO 2008072621 A1 WO2008072621 A1 WO 2008072621A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- progrp
- serum
- plasma
- sample
- storage
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5758—Gastrin releasing peptide
Definitions
- the present invention relates to an assay method for dramatically improving specimen stability by using plasma as a sample in a ProGRP (gastrin releasing peptide precursor) detection system based on immunological measurement.
- ProGRP gastrin releasing peptide precursor
- Patent Document 1 JP-A-6-98794
- ProGRP 31-98 is still less stable than normal antigens used for immunological measurements.
- the tolerance of the decrease in ProGRP31—98 activity in the sample seems to vary from manufacturer to manufacturer.
- Case Refrigerated samples are only allowed to be stored for up to 24 hours (both are approved diagnostics by the Ministry of Health, Labor and Welfare) and are not allowed to be stored at room temperature. Since the stability in plasma and serum is interpreted as equivalent, only measurement using serum has been put into practical use. When storing serum samples for more than 3 to 24 hours, it is necessary to freeze the samples, and it is necessary to thaw before use, and to remove precipitates generated by freeze-thawing by centrifugation before measurement. Insufficient specimen stability, for example, significantly reduced work efficiency.
- antigens such as typical cancer markers such as CEA, AFP, and CA19-9, that are immunologically measured, can exist stably up to 7 days in refrigerated storage. This is also a cause of a decrease in the efficiency of the entire examination, such as the need for a special operation 'storage place only when performing the inspection.
- ProGRP is a protein with a molecular weight of 8000-10000, and ProGRP 31-98 is used for immunoassay! /, And the molecular weight of the region from the 31st to the 98th amino acid sequence is about 7800. is there. It is known as a general fact that the molecular weight is low! / The peptide molecule has poor sample stability! / And it can be convinced that no research has been reported on the cause of ProGRP's poor sample stability. . However, there are peptide molecules that can exist stably for more than 5 days in refrigerated storage in serum plasma, even if the molecular weight is small, such as insulin (molecular weight 5800) used as an immunodiagnostic drug. Therefore, the inventor considered that there is some kind of specimen destabilization mechanism peculiar to ProGRP in addition to the small molecular weight.
- the destabilizing factor in the sample is the destabilization that exists in blood, not just ProGRP itself. The inventors thought that this was due to the presence of the leading material.
- the GRP part which is a physiologically active site (from the first amino acid sequence) 27) is already included! /, And! /, Therefore, the inventor believes that some reaction other than the reaction that occurs in vivo may cause ProGRP-specific analyte instability.
- blood coagulation factors and fibrinolytic factors are activated, each of which is a blood coagulation factor precursor molecule. It is a well-known fact that it leads to the activation of thrombin resulting from the degradation and activation of prothrombin, and to the formation of fibrin by the fibrinogen degradation reaction by thrombin. is there. The liquid component from which the coagulated portion is removed becomes serum.
- activated forms of blood coagulation factors are mostly proteolytic enzymes, including thrombin, and are present in serum. In plasma, thrombin is not activated, and some blood coagulation factors are not activated due to the type of anticoagulant.
- serum contains a larger amount of blood coagulation factor, activator of fibrinolytic factor, and degradation substance than in vivo and plasma. Therefore, the inventors existed in the serum! /, And did not exist in the living body! /, Or only in trace amounts! /, N! / ⁇ These substances and the anxiety of ProGRP 31-98 I thought that power that is related to qualitative might not.
- thrombin which is one of the active substances of the blood coagulation factor
- the inventor added thrombin, which is one of the active substances of the blood coagulation factor, to the Pro oGRP solution and observed a decrease in the activity. From these results, it was clarified that thrombin, which is one of the activators of blood coagulation factors, contributes to the decrease in ProGRP activity.
- the inventor makes use of the property that blood coagulation factor active substances are present in a large amount in serum and are not present in the living body or in plasma at all or only in a trace amount, and sample plasma.
- the stability of ProGRP was studied, and the specimen stability of ProGRP was successfully improved.
- the present invention was thus completed.
- Plasma can be collected from blood in the same manner as serum, and can be collected from blood almost in the same manner as serum, and can be used for immunoassays without any problem. Further, the same effect can be obtained by adding an inhibitor or an inactivating agent of an activated form of blood coagulation factor or fibrinolytic factor to the serum sample.
- the present invention is more convenient and more accurate than the conventional method by using a blood sample in which blood coagulation factors are not activated, and thus no fibrin formation occurs and blood coagulation does not occur. It provides a ProGRP measurement method that enables accurate measurement.
- V means a blood sample in which a drug that suppresses or reduces the activation of any one of the blood clotting factors is added or the blood clotting factor is removed.
- Agents such as EDTA, heparin, and citrate can be used as agents that suppress or reduce the activation of blood coagulation factors, but are not limited thereto.
- plasma as a blood sample in a state where blood coagulation does not occur.
- all plasma samples used in the test can be used. That is, EDTA plasma, heparin plasma, citrate plasma are representative examples, and other plasmas are included.
- the salt used for each substance can also be selected arbitrarily. For EDTA, 2K, 3 ⁇ , for heparin, sodium salt, lithium salt, and other powers are also available.
- an effect can be obtained by adding a substance that inactivates blood coagulation factors to the serum after serum collection, removing blood coagulation factors, or reducing the activity. Is possible.
- the present invention can be used in any measurement system for measuring force ProGRP that is suitable for use in an immunological measurement method.
- a sample can be stored stably for a long period of time.
- the storage period of 3-24 hours can be extended to about one week.
- it can be stored at room temperature.
- the present invention even when the storage time of the sample exceeds 3-24 hours, it is not necessary to store the sample in a frozen state.
- the work efficiency can be remarkably improved, for example, the work to be performed becomes unnecessary.
- Ma Many other antigens that are measured immunologically can be stored stably in refrigerated storage, and can be stored for one week, so there are special storage procedures and storage locations for ProGRP measurement samples. It becomes unnecessary.
- the present invention improves the long-term specimen stability in cryopreservation, and further improves the stability at room temperature, so that it is possible to save the labor of separating and storing serum in a refrigerated state. . Furthermore, since the present invention can suppress a decrease in activity in room temperature work that is inevitably caused in the process from blood collection to the end of measurement, the ProGRP value can be measured more accurately.
- the present invention is a new invention based on a mechanism completely different from any of the conventional techniques, It has the power and effects that cannot be expected with conventional technology.
- ProGRP 31-98 antigen obtained from Abbott Laboratories, USA was added to a phosphate buffer containing 1% bovine serum albumin and 2 mM calcium chloride by amino acid synthesis using the Fmoc method. Furthermore, thrombin (manufactured by Sigma-Aldrich) was added, and after storage at room temperature, the ProGRP concentration was measured using Architect ProGRP. The measurement results are shown in Fig. 1. From Fig. 1, ProGRP degradation is observed in the presence of thrombin. It is suggested that thrombin is involved as a major cause of oGRP degradation. Thrombin is an activator of blood coagulation factor II and is a substance present in large amounts in serum. The Architect measurement method is described in Example 3.
- PMSF Sigma Aldrich
- ProGRP 31-98 antigen synthesized with the amino acid by the Fmoc method was added and stored at room temperature, and then the ProGRP concentration was measured using Architect ProGRP.
- the measurement results are shown in Fig. 2.
- Figure 2 shows that the decrease in ProGRP activity is significantly suppressed in the presence of PMSF.
- PMSF is a substance used to inactivate the enzyme activity of serine proteases such as thrombin.
- the abundance of proteases such as thrombin S and ProGRP are inactivated by V. Can be considered.
- ProGRP 31-98 (obtained from Abbott Laboratories, USA) synthesized by the Fmoc method was added to serum and EDTA plasma obtained from the same blood donor, and used as a measurement sample. The measurement samples were stored for 1 day, 3 days, and 7 days in a refrigerator and stored at room temperature for 1 day, and then the ProGR P concentration was measured. For the measurement of ProGRP concentration, Serum Lab (registered trademark) ProGRP measurement kit (Fujirebio) and Architect ProGRP described below were used. The measurement results are shown in Figs.
- ProGRP can not be stably stored until 1 day (next day) under refrigerated storage conditions, but when plasma is used, it can be stably stored for more than 1 week.
- ProGRP residual rate e kt according to the approximate expression of the deactivation rate in general substances shown by Evans et al. (Clinical Biochemistrv 34, pages 107-112, 2001) (e: natural logarithm, k: constant, t: time) Approximate time required for the survival rate to show 90% is refrigerated using the Serum Lab® ProGRP measurement kit for 7 days. Using the measured value, it is calculated as 10.25 days for refrigeration. Similarly, in the case of serum 1.
- ProGR P survival rate e kt (e: natural logarithm, k: constant, t: time)
- the time required for the survival rate to show 90% is measured at the serum laboratory at room temperature for 24 hours. Using this, it is calculated as 58 hours, and even at room temperature, it can be stably stored for up to 2 days.
- Anti-ProGRP 31-98 antibody (antibody obtained according to the method described in Japanese Patent No. 3210994) was obtained on EDC (N-ethyl-N '-(3) on carboxyl group-modified magnetic fine particles (obtained from Abbott Laboratories, USA).
- EDC N-ethyl-N '-(3) on carboxyl group-modified magnetic fine particles (obtained from Abbott Laboratories, USA).
- —Dimethylaminopropyl) carpositimide hydrochloride manufactured by Sigma-Aldrich
- An antibody-immobilized microparticle solution was prepared by adding to a Tris-HCl buffer containing sodium acetate salt) and sodium chloride.
- Anti-ProGRP 31-98 antibody (antibody obtained according to the method described in Patent 3210994) is labeled with ataridinium derivative (obtained from Abbott Laboratories, USA), and the surfactant, bovine serum albumin (Sigma Aldrich)
- the labeling solution was prepared by adding the solution to a MES buffer containing
- the first reaction was initiated by mixing 50 ul of the sample with the antibody-immobilized microparticle solution. During the first reaction, ProGRP antigen binds to the antibody-immobilized magnetic particles, and the amount of the binding corresponds to the ProGRP concentration in the sample. After 18 minutes, the antibody-immobilized magnetic particles are held with a magnet and washed with the phosphate buffer dedicated to this unit! / ⁇ Further labeled solution 50 ul of the liquid was mixed and the reaction was continued for 4 minutes. This reaction causes the labeled antibody to bind to ProGRP on the magnetic particles.
- the amount of labeled antibody binding depends on the amount of ProGRP on the magnetic particles, so if the ProGRP concentration in the sample is low, a small amount of labeled antibody binds to the magnetic particles, and if the ProGRP concentration in the sample is high, a large amount The labeled antibody will bind to the magnetic particles.
- a luminescence signal was observed using a luminescence pre-trigger reagent “trigger reagent” dedicated to this machine.
- a standard curve was prepared by a logistic 4-para method using a separately prepared solution with a known concentration as the standard solution, and the ProGRP concentration in the sample was determined by calculating the signal obtained from Sampnore as the ProGRP concentration.
- EDTA plasma, lithium heparin plasma, citrate plasma, sodium heparin plasma, and serum matched samples obtained from the same donor are supplemented with recombinant ProGRP 31-98 obtained according to the method described in Patent 3210994.
- the sample was stored at room temperature for 24 hours or while refrigerated for 7 days, and the ProGRP concentration was measured in the same manner as in Example 3.
- the value obtained by dividing the measured value of the sample left at room temperature for 24 hours by the measured value at time 0 is the ProGR P remaining rate after storage at room temperature for 24 hours, and the measured value of the sample stored refrigerated for 7 days is the measured value at time 0
- the value obtained by dividing the value by 3 was used as the ProGRP remaining rate after refrigerated storage for 7 days.
- Fig. 7 shows the ProGRP residual rate after refrigerated storage for 7 days in various plasmas.
- Fig. 8 shows the percentage of ProGRP remaining in various plasmas after storage at room temperature for 24 hours. 7 and 8, it can be seen that both plasmas are significantly higher than serum, that is, the sample stability is significantly improved in any plasma. In addition, the 100% survival rate was shown in plasma when stored for 7 days in refrigeration, indicating that almost all ProGR P was stably stored until 7 days in plasma.
- ProGRP 31-98 antigen synthesized by Fmoc method was added to EDTA plasma / serum match specimens obtained from the same blood donor, stored at room temperature and refrigerated, then ProGRP 31 Concentration was measured. Values up to 24 hours are the average of 3 donors, 72 Values up to the time are shown as average values from two donors.
- Fig. 9 shows the ProGRP survival rate in refrigerated storage
- Fig. 10 shows the ProGRP residual rate in room temperature storage. The storage times shown in the figure are 0, 1, 3, 6, 7, 9, 24 hours (refrigerated storage and room temperature storage so far) and 72 hours (refrigerated storage only).
- Serum plasma has equivalent ProGRP stability in storage for up to 6 hours. However, after 6 hours, the difference gradually becomes significant, and when the ProGRP specimen is stored for more than 24 hours, plasma can clearly show superior stability compared to serum.
- the residual rate of activity is about 90% whether stored at room temperature or for 24 hours, and can be stored stably up to about 24 hours.
- Yamaguchi et al. Show that plasma can be used within the range where it can be stably present in serum.
- the present invention is a blood sample even under storage conditions and storage time that cannot exist stably in serum.
- ProGRP is a different from Yamaguchi et al.'S invention in that it can secure sufficient storage stability sufficient for use as a diagnostic agent, and the usefulness of the present invention can be demonstrated. Can do.
- FIG. 1 shows the survival rate of ProGRP when stored at room temperature in the presence, absence, and serum of thrombin.
- FIG. 2 shows the residual ratio of ProGRP when stored at room temperature in serum with and without PMSF added.
- FIG. 3 shows the residual ratio of ProGRP after refrigerated storage in serum and plasma.
- FIG. 4 shows the residual ratio of ProGRP after storage at room temperature in serum and plasma.
- FIG. 5 shows the residual ratio of ProGRP after refrigerated storage in serum and plasma.
- FIG. 6 shows the residual ratio of ProGRP after storage at room temperature in serum and plasma.
- FIG. 8 Shows the residual ratio of ProGRP in serum and plasma after storage at room temperature for 24 hours.
- FIG. 9 shows the residual rate of ProGRP after refrigerated storage in serum and plasma.
- FIG. 10 shows the residual ratio of ProGRP after storage at room temperature in serum and plasma.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012011711A MX340107B (es) | 2006-12-11 | 2007-12-11 | Metodo de medicion inmunologica para precurso de peptido que libera gastrina. |
MX2009006168A MX2009006168A (es) | 2006-12-11 | 2007-12-11 | Metodo de medicion inmunologica para precursor de peptido que libera gastrina. |
EP07850416.4A EP2103938B1 (en) | 2006-12-11 | 2007-12-11 | Immunological measurement method for gastrin-releasing peptide precursor |
US12/518,610 US20100136711A1 (en) | 2006-12-11 | 2007-12-11 | Immunoassay method for pro-gastrin-releasing peptide |
ES07850416.4T ES2601028T3 (es) | 2006-12-11 | 2007-12-11 | Método de medición inmunológica para el precursor del péptido liberador de gastrina |
US14/295,116 US9459248B2 (en) | 2006-12-11 | 2014-06-03 | Immunoassay method for pro-gastrin-releasing peptide |
US15/283,828 US10067124B2 (en) | 2006-12-11 | 2016-10-03 | Immunoassay method for pro-gastrin-releasing peptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006333072A JP5201822B2 (ja) | 2006-12-11 | 2006-12-11 | ガストリン放出ペプチド前駆体の免疫学的測定方法 |
JP2006-333072 | 2006-12-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/518,610 A-371-Of-International US20100136711A1 (en) | 2006-12-11 | 2007-12-11 | Immunoassay method for pro-gastrin-releasing peptide |
US14/295,116 Continuation US9459248B2 (en) | 2006-12-11 | 2014-06-03 | Immunoassay method for pro-gastrin-releasing peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008072621A1 true WO2008072621A1 (ja) | 2008-06-19 |
Family
ID=39511642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/073854 WO2008072621A1 (ja) | 2006-12-11 | 2007-12-11 | ガストリン放出ペプチド前駆体の免疫学的測定方法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US20100136711A1 (ja) |
EP (1) | EP2103938B1 (ja) |
JP (1) | JP5201822B2 (ja) |
ES (1) | ES2601028T3 (ja) |
MX (2) | MX2009006168A (ja) |
WO (1) | WO2008072621A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9459248B2 (en) | 2006-12-11 | 2016-10-04 | Abbott Laboratories | Immunoassay method for pro-gastrin-releasing peptide |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20115367A0 (fi) * | 2011-04-15 | 2011-04-15 | Hytest Oy | Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja |
CN108333360A (zh) * | 2017-01-19 | 2018-07-27 | 深圳市新产业生物医学工程股份有限公司 | 胃泌素释放肽前体稀释液及其应用和试剂盒 |
CN108107224A (zh) * | 2017-12-18 | 2018-06-01 | 郑州安图生物工程股份有限公司 | 一种ProGRP含量测定用液态校准品 |
CN108279307B (zh) * | 2018-01-30 | 2021-01-26 | 郑州安图生物工程股份有限公司 | 保护和稳定血清或血浆中胃泌素释放肽前体的采血管 |
CN108982858B (zh) * | 2018-07-05 | 2021-06-15 | 陕西师范大学 | 一种基于单克隆抗体检测人proGRP的双夹心ELISA试剂盒 |
CN109342728A (zh) * | 2018-10-18 | 2019-02-15 | 郑州标源生物科技有限公司 | 一种适用肿瘤标志物Pro-GRP定量检测的质控品 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0698794A (ja) * | 1992-06-12 | 1994-04-12 | Tonen Corp | ヒトガストリン放出ペプチド前駆体に対する抗体及びその使用 |
JP2003270238A (ja) * | 2002-03-14 | 2003-09-25 | Sanyo Chem Ind Ltd | 体液検査用具 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256540A (en) * | 1990-12-28 | 1993-10-26 | Mayo Foundation For Medical Education And Research | Immunoassay for small cell lung carcinoma |
CA2089212C (en) * | 1992-06-12 | 2004-01-20 | Ken Yamaguchi | Antibodies to human gastrin-releasing peptide precusor and use thereof |
CA2604608C (en) * | 2005-04-13 | 2013-11-19 | Advanced Life Science Institute, Inc. | Antibody directed against gastrin-releasing peptide precursor and use thereof |
US20080160545A1 (en) * | 2006-09-05 | 2008-07-03 | Abbott Laboratories | Pro-GRP as a surrogate marker to predict and monitor response to Bcl-2 inhibitor therapy |
WO2008029965A1 (en) * | 2006-09-08 | 2008-03-13 | Peoplebio, Inc. | Simultaneous reaction assay for differentially detecting multimeric form |
JP5201822B2 (ja) | 2006-12-11 | 2013-06-05 | アボット・ラボラトリーズ | ガストリン放出ペプチド前駆体の免疫学的測定方法 |
-
2006
- 2006-12-11 JP JP2006333072A patent/JP5201822B2/ja active Active
-
2007
- 2007-12-11 MX MX2009006168A patent/MX2009006168A/es active IP Right Grant
- 2007-12-11 EP EP07850416.4A patent/EP2103938B1/en active Active
- 2007-12-11 MX MX2012011711A patent/MX340107B/es unknown
- 2007-12-11 WO PCT/JP2007/073854 patent/WO2008072621A1/ja active Application Filing
- 2007-12-11 US US12/518,610 patent/US20100136711A1/en not_active Abandoned
- 2007-12-11 ES ES07850416.4T patent/ES2601028T3/es active Active
-
2014
- 2014-06-03 US US14/295,116 patent/US9459248B2/en not_active Expired - Fee Related
-
2016
- 2016-10-03 US US15/283,828 patent/US10067124B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0698794A (ja) * | 1992-06-12 | 1994-04-12 | Tonen Corp | ヒトガストリン放出ペプチド前駆体に対する抗体及びその使用 |
JP3210994B2 (ja) | 1992-06-12 | 2001-09-25 | 株式会社先端生命科学研究所 | ヒトガストリン放出ペプチド前駆体に対する抗体及びその使用 |
JP2003270238A (ja) * | 2002-03-14 | 2003-09-25 | Sanyo Chem Ind Ltd | 体液検査用具 |
Non-Patent Citations (3)
Title |
---|
BOYANTON ET AL., CLINICAL CHEMISTRY, vol. 48, 2002, pages 2242 - 2247 |
EVANS ET AL., CLINICAL BIOCHEMISTRY, vol. 34, 2001, pages 107 - 112 |
See also references of EP2103938A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9459248B2 (en) | 2006-12-11 | 2016-10-04 | Abbott Laboratories | Immunoassay method for pro-gastrin-releasing peptide |
US10067124B2 (en) | 2006-12-11 | 2018-09-04 | Abbott Laboratories | Immunoassay method for pro-gastrin-releasing peptide |
Also Published As
Publication number | Publication date |
---|---|
US20170089889A1 (en) | 2017-03-30 |
US10067124B2 (en) | 2018-09-04 |
US9459248B2 (en) | 2016-10-04 |
US20100136711A1 (en) | 2010-06-03 |
EP2103938A4 (en) | 2010-06-30 |
EP2103938B1 (en) | 2016-08-31 |
EP2103938A1 (en) | 2009-09-23 |
ES2601028T3 (es) | 2017-02-14 |
MX2009006168A (es) | 2009-06-19 |
JP5201822B2 (ja) | 2013-06-05 |
JP2008145278A (ja) | 2008-06-26 |
MX340107B (es) | 2016-06-27 |
US20140287532A1 (en) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10067124B2 (en) | Immunoassay method for pro-gastrin-releasing peptide | |
Wolf | A modification for routine laboratory use of Stefanini's method of estimating factor V activity in human oxalated plasma | |
Smith et al. | Correlation of hematocrit, platelet concentration, and plasma coagulation factors with results of thromboelastometry in canine whole blood samples | |
US7294479B2 (en) | Compositions, kit and one-step method for monitoring compounds having anti-factor Xa and/or anti factor IIa activities | |
Zugker et al. | Preparation of quality control specimens for coagulation | |
Nilsson et al. | The measurement of fibrinolytic activities | |
WO2020116556A1 (ja) | フィブリノゲン測定試薬 | |
AU2004239468B2 (en) | Activation mixture | |
US6368785B1 (en) | Anti-coagulation of blood, plasma or synovial fluid products using iso-citrate | |
Tammen et al. | Collection and handling of blood specimens for peptidomics | |
Davey et al. | Gamma globulin inhibition of fibrin clot formation | |
EP2943796B1 (en) | In vitro method, use of an agent and collection device for the inhibition of coagulation in blood | |
Deng et al. | Sample Collection for Targeted Biomarker Quantitation by LC–MS | |
US5114845A (en) | Assays for plasminogen activator inhibitor and soluble fibrin | |
WO2014194922A1 (ru) | Набор для измерения параметров системы гемостаза в образце крови или ее компонентов | |
CN103959068B (zh) | 基于纤溶酶原激活物抑制剂-1的流产、早产治疗药 | |
Onundarson | Screening tests for bleeding disorders | |
CN115201499A (zh) | 一种稳定性强的活化凝血测定试剂 | |
JP2000146954A (ja) | 血清・血漿検体中のフィブリンを溶解する方法 | |
JPH06331628A (ja) | 抗リン脂質抗体の測定方法 | |
Seegers et al. | Wayne State University College of Medicine, Detroit: Seventh Annual: Symposium on Blood January 17th and 18th, 1958 | |
Innocente | Blood Coagulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07850416 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
REEP | Request for entry into the european phase |
Ref document number: 2007850416 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007850416 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/006168 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12518610 Country of ref document: US |